Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs.

Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, Apte A, Arnold K, Zacharek SJ, Iliou MS, Bhatt K, Garnaas M, Musenge F, Davis A, Khatwani N, Su SV, MacLean G, Farlow SJ, Burke K, Frederick JP.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat9143. doi: 10.1126/scitranslmed.aat9143.

PMID:
30700577
2.

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct.

Jain R, Frederick JP, Huang EY, Burke KE, Mauger DM, Andrianova EA, Farlow SJ, Siddiqui S, Pimentel J, Cheung-Ong K, McKinney KM, Köhrer C, Moore MJ, Chakraborty T.

Nucleic Acid Ther. 2018 Oct;28(5):285-296. doi: 10.1089/nat.2018.0734. Epub 2018 Aug 8.

4.

A chimera of a gelatinase inhibitor peptide with streptavidin as a bifunctional tumor targeting reagent.

Farlow SJ, Wang RJ, Pandori MW, Sano T.

FEBS Lett. 2002 Apr 10;516(1-3):197-200.

5.

Novel dendritic kinesin sorting identified by different process targeting of two related kinesins: KIF21A and KIF21B.

Marszalek JR, Weiner JA, Farlow SJ, Chun J, Goldstein LS.

J Cell Biol. 1999 May 3;145(3):469-79.

6.

The dynein gene family in Chlamydomonas reinhardtii.

Porter ME, Knott JA, Myster SH, Farlow SJ.

Genetics. 1996 Oct;144(2):569-85.

7.

Red cell antibody identification by solid phase red cell adherence utilizing dried RBC monolayers.

Stone DL, Eatz RA, Rolib SD, Farlow SJ, Hudson GS, Sinor LT.

Immunohematology. 1990;6(1):12-7.

PMID:
15945979

Supplemental Content

Loading ...
Support Center